Optimum Customers: Your Newsday access has been extended until Oct 1st. Enroll now to continue your access.

LEARN MORE
TODAY'S PAPER
67° Good Evening
67° Good Evening
Business

AstraZeneca to pay Chembio up to $2.9 million to develop test

In announcing the deal, the pharmaceutical giant and the Medford company did not disclose which biomarker the new test will detect.

A Chembio Diagnostics scientist works at the Medford

A Chembio Diagnostics scientist works at the Medford company. Photo Credit: Newsday / John Paraskevas

A Medford manufacturer of diagnostic tests has teamed with pharmaceutical giant AstraZeneca to develop a test to detect a biomarker or substance that shows a disease or infection is present in the body, officials said.

Chembio Diagnostics Inc. said it will receive up to $2.9 million from AstraZeneca, the Cambridge, England-based seller of the acid reflux medicine Nexium and other drugs, for the new test.

The companies did not disclose the specific biomarker that the test will detect.

Chembio, with sales of $18 million in 2016, is best known for developing rapid blood tests used to diagnose HIV, syphilis, Ebola, Zika and other tropical diseases.

The company announced last month the successful completion of U.S. tests in humans of a new combination HIV and syphilis test. It plans to seek permission from the U.S. Food and Drug Administration to begin selling the test and a companion results reader.

CEO John Sperzel said last month the research agreement with AstraZeneca will “leverage” Chembio’s testing technology “to develop and commercialize a novel point-of-care diagnostic test.”

AstraZeneca, a British and Swedish company, produces drugs to treat cancer, heart disease, stomach ailments, respiratory diseases and inflammation. It posted sales of $23 billion in 2016.

More news